Form 4: Hoth Therapeutics CEO Robb Knie Acquires 25,000 Shares of Common Stock
SEC Form 4 Filing
Hoth Therapeutics CEO Robb Knie purchased 25,000 shares of common stock at $0.67 per share on August 16, 2024.
Summary
- On August 16, 2024, Robb Knie, CEO and President of Hoth Therapeutics, Inc., acquired 25,000 shares of common stock.
- The purchase price was $0.67 per share.
- Following the transaction, Knie directly owns 58,131 shares of Hoth Therapeutics common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider buying can be seen as a positive signal, but without more context, it's difficult to gauge the overall impact.
Positives
- The CEO's purchase of company stock may signal confidence in the company's future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders of a company (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. These filings provide transparency to the market regarding insider transactions.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive sign of confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 08/16/2024 | Date of transaction: Robb Knie acquired 25,000 shares of common stock. |
| 08/19/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.